



The use of CSF biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials

Journal:	<i>Expert Review of Neurotherapeutics</i>
Manuscript ID	Draft
Manuscript Type:	Reviews
Keywords:	CSF, biomarkers, clinical trial, Alzheimer's disease, neurodegeneration

SCHOLARONE™
Manuscripts

Abstract

Introduction

All recent phase 3 trials of potentially disease-modifying therapies for Alzheimer's disease (AD) have so far failed. Potential reasons include enrolling subjects whose disease is too advanced or who do not have AD pathology, or simply incorrect drug targets. The goal of disease-modifying AD trials is to halt the progress of neuronal damage and death and this can be assessed *in vivo* is using CSF biomarkers.

Area covered

We conducted a literature search of the use of CSF biomarkers in disease-modifying AD clinical trials using PubMed. We show that CSF biomarkers have only sparsely been used as outcome measures, and where they have, only in small subsets of patients. No clinical trials have yet showed any substantial effects on CSF biomarkers of neurodegeneration.

Expert commentary

In future trials, we advocate that CSF biomarkers be used more extensively to optimize the chance of detecting positive drug effects. This includes the identification of potential AD patients - already in the early prodromal stage – for inclusion, for stratification, as readout i.e. proximity markers for changes in axonal/neurodegeneration between treatment and placebo groups – this also enables proof of principle verification in the discovery/dose finding phase, and for monitoring of side effects.

Introduction

Alzheimer's disease (AD) is typically characterized by progressive memory loss, difficulty in planning and execution of everyday activities, language problems, disorientation and changes

1
2
3 in personality. AD is the most common neurodegenerative disease, accounting for 60-80% of
4
5 all cases with dementia. The prevalence of AD in populations older than 65 years is
6
7 approximately 11%, rises with age, with a lifetime risk of 10–20% [1-3]. The pathological
8
9 hallmarks of AD, first described by Alois Alzheimer in 1907, are the presence of senile
10
11 plaques now known to contain the 42 amino acid form of amyloid- β (A β 42) and
12
13 neurofibrillary tangles shown to be formed from the aggregation of a hyperphosphorylated
14
15 form of the microtubule-associated protein tau [1,4,5]. The dominant hypothesis of AD
16
17 pathogenesis – the amyloid hypothesis – suggests that the disease process is initiated by β -
18
19 amyloid deposition, which leads to tau phosphorylation and tangle formation and
20
21 subsequently neuronal cell death [6]. This hypothesis has guided the development of most
22
23 drugs aiming to modify the pathology of AD in clinical trials. In this review, we give an
24
25 updated account and considered critique on how CSF biomarkers have been used in attempts
26
27 to detect beneficial effects of disease-modifying drug candidates on the neurodegenerative
28
29 process in AD.
30
31
32
33
34
35
36

37 **CSF biomarkers for core pathological changes in AD**

38 **Total tau**

39
40 Total tau (T-tau), measured using assays with antibodies against mid-domain non-
41
42 phosphorylated epitopes of tau, can be used as a general marker of neuroaxonal
43
44 degeneration/injury in AD. AD patients have increased CSF T-tau concentrations [7], and the
45
46 higher the increase, the more intense neurodegenerative process [8]. However, CSF T-tau
47
48 increase is not specific for AD, and is for example seen in Creutzfeldt-Jakob disease (CJD)
49
50 [9] and following stroke [10].
51
52
53
54
55
56
57
58
59
60

Phosphorylated tau

Phosphorylated tau (P-tau) is the main component of neurofibrillary tangles [11]. Tau can be phosphorylated at many different epitopes but the most commonly used assays are those specific for tau phosphorylated at amino acid 181 or 231. CSF levels of P-tau are increased in AD [7] and correlate with cognitive decline in patients with mild cognitive impairment (MCI) and with neocortical neurofibrillary pathology in AD [12]. Increased CSF levels of P-tau are associated with rapid progression of MCI to AD [13] and also the intensity of AD [14].

Amyloid β

Several lines of evidence link the 4 kDa form of beta-amyloid (A β 42) to AD. First, A β 42, generated by the sequential cleavage of the amyloid precursor protein (APP) by BACE1 and γ -secretase, is highly aggregation prone and is the main component of senile plaques which are characteristic for AD [15,16]. Second, several mutations in the *APP* gene result in familial AD [17]. Third, a number of mutations in the presenilin 1 and 2 genes that are part of the γ -secretase complex also results in familial AD [18,19]. Fourth, patients with Down syndrome due to trisomy 21 where the *APP* gene is localized develop AD at an early age [20]. AD is associated with low CSF levels of A β 42, which is thought to reflect deposition of the protein in the brain parenchyma [21]; low levels of A β 42 can be used not only to aid in AD diagnosis [22], but also to predict conversion from MCI to AD [7,23].

Another form of beta-amyloid is A β 40 which is the predominant form of beta-amyloid in CSF. A β 40 is identical to A β 42 except for two less amino acids at the C-terminal end. There are no differences in CSF A β 40 levels between AD and controls [7] but A β 40 can be used as an estimate of A β production in an individual. Thus, the ratio between A β 42/A β 40 is more informative in AD since A β 42 can be naturally low in low producers without amyloid pathology, which would then be reflected in a normal A β 42/A β 40 ratio [24].

CSF biomarkers of axonal and synaptic degeneration in AD

Neurofilament light protein

Another CSF biomarker for axonal degeneration is neurofilament light protein (NFL), a structural protein in long axons [25]. CSF NFL concentrations are increased in AD [7] and especially in patients with rapid disease progress [26]. NFL is however not specific for AD; the highest concentrations are seen in FTD and vascular dementia (VaD) [27-29] as recently confirmed in a large retrospective analysis of data from the Swedish Dementia Registry [30]; and NFL is also elevated in atypical parkinsonian disorders [31,32] and motor neuron disease [33]. As with T-tau, the highest CSF concentrations of NFL are seen in CJD [34,35].

Neurogranin

Neurogranin (Ng) is a neural-enriched dendritic protein involved in long-term potentiation of synapses, particularly so in the hippocampus and basal forebrain. Recently, several independent studies have shown that the CSF concentrations of Ng are increased in AD [36-40], but not in other neurodegenerative disorders [41], and that Ng predicts future cognitive decline, brain atrophy and reduction in glucose metabolism in prodromal disease stages [42,43]. Currently, CSF Ng is the most evaluated CSF biomarker for synapse loss or dysfunction in AD, although there are other promising markers (e.g. SNAP-25, Rab3A) in various stages of development [44,45].

Clinical trials with CSF biomarker data

AN1792

The first clinical trial of active A β immunization was with AN1792 consisting of full length aggregated A β 42 combined with the QS-21 adjuvant. In this phase 2 trial, 372 AD patients with AD (mini-mental state examination (MMSE) score 15-26) were included. Patients were

1
2
3 randomized (4:1) to receive an intramuscular injection of 225 µg AN1792 or placebo at day 0,
4
5 month 1 and month 3. The study was designed to include injections at month 6, 9 and 12 but
6
7 was discontinued due to adverse events, with a 6% rate of meningoencephalitis [46]. There
8
9 were no effects on memory or cognition in this shortened trial. CSF biomarkers were analyzed
10
11 in a subset of patients; 11 antibody responders (anti-AN1792 IgG titer $\geq 1:2,200$) and 10 in the
12
13 placebo group. There were no significant changes in CSF A β 42 between groups, but there
14
15 was a significant decrease in CSF T-tau towards normal levels in antibody responders vs.
16
17 placebo.
18
19

20 21 **Bapineuzumab**

22
23 Bapineuzumab is the humanized form of the mouse monoclonal antibody 3D6 that recognizes
24
25 the first five amino acids of A β 42 [47]. Two multicenter phase 2 studies of bapineuzumab (
26
27 201 and 202) were performed. The 201 study included 234 AD patients with an MMSE score
28
29 of 16-26 randomised to bapineuzumab (n=124) or placebo (n=110). Bapineuzumab was dosed
30
31 at 0.15, 0.5, 1.0 or 2.0 mg/kg at six occasions, 13 weeks apart, and patients were followed for
32
33 78 weeks [48]. The 202 study comprised 28 AD patients with an MMSE score of 18-26; 20
34
35 patients received 0.5, 1.0 or 2.0 mg/kg of bapineuzumab and 8 patients received placebo [49].
36
37 There was no treatment effect on cognition in either of these studies. CSF biomarkers were
38
39 analyzed in a combined subset of these two studies. In total, 46 patients had paired CSF data
40
41 at baseline and at week 54; 27 had received bapineuzumab and 19 placebo [50]. T-tau
42
43 decreased by 72.3 pg/ml (from 811.3 \pm 466.3 to 739 \pm 336.8) in the bapineuzumb group
44
45 compared to 5.6 pg/ml (from 1077.9 \pm 935.1 to 1072.4 \pm 972.8 pg/ml) in the placebo group
46
47 (P=0.03). A significant difference in decrease in P-tau was also observed between the
48
49 bapineuzumab group (baseline: 97.0 \pm 41.3 pg/ml, week 54: 87.1 \pm 31.0 pg/ml) compared to the
50
51 placebo (baseline: 105.3 \pm 49.8 pg/ml, week 54: 102.7 \pm 47.8 pg/ml), e.g. -9.9 vs -2.6 pg/ml
52
53
54
55
56
57
58
59
60

1
2
3 (P=0.001). However, there was no difference in change between baseline and week 54 for
4
5 A β 42 (-10.5 vs -6.1 pg/ml for bapineuzumab vs. placebo, P=0.44).
6
7

8 Bapineuzumab has since been tested in two large multicenter phase 3 studies – one of *APOE*
9 ϵ 4 positive individuals (carriers), and one of *APOE* ϵ 4 non-carriers. In the carrier study, 1090
10 individuals with 1 or 2 copies of the ϵ 4 allele received either 0.5 mg/kg bapineuzumab
11 (n=658, MMSE=20.7 \pm 3.2) or placebo (n=432, MMSE=20.8 \pm 3.1) every 13 weeks up to week
12 78 [51]. In the non-carrier study of 1114 AD patients without an *APOE* ϵ 4 allele, patients
13 received either 0.5 mg/kg bapineuzumab (n=314, MMSE=21.2 \pm 3.4), 1.0 mg/kg
14 bapineuzumab (n=307, MMSE=21.2 \pm 3.3) or placebo (n=493, MMSE=21.2 \pm 3.2) every 13
15 weeks up to week 78 [51]. There was no significant effect on cognition in either study. P-tau
16 was the only CSF biomarker that was analyzed, in 212 patients in the carrier study and in 178
17 patients in the non-carrier study. In the carrier study, P-tau decreased from 108.9 \pm 38.7 to
18 103.4 \pm 37.3 pg/ml in the bapineuzumab group and increased from 119.9 \pm 50.7 to 121.1 \pm 54.9
19 pg/ml in the placebo group (-5.8 vs. +0.9 pg/ml, P=0.005) from baseline to week 71. In the
20 non-carrier study, P-tau decreased from 97.5 \pm 50.6 to 94.1 \pm 45.56 in the combined
21 bapineuzumab group and from 104.2 \pm 47.8 to 101.3 \pm 47.4 in placebo, but this was not
22 significant (-3.4 vs. -2.9, P=0.11).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Solanezumab**

43 Solanezumab is a humanized version of the of the mouse monoclonal antibody m266 that
44 recognizes amino acids 13-28 in A β 42 [52]. In a 12 week phase 2 study, 52 AD patients
45 received solanezumab at either 100 mg weekly, 100 mg every four weeks, 400 mg weekly,
46 400 mg every four weeks or placebo for a total of 12 weeks [53]. Repeated CSF sampling was
47 only available in a subgroup of patients. The number of patients in each group was low and no
48 clear effects were observed between baseline and after 12 weeks on CSF T-tau or P-tau levels
49 between treatment and placebo groups. Thus the change in the placebo group (n=8) was -
50
51
52
53
54
55
56
57
58
59
60

1
2
3 4.1% for T-tau and -2.1% P-tau; in the 100 mg every fourth week group (n=8) +0.7% for T-
4 tau and -2.1% for P-tau; in the 100 mg weekly group (n=8) -3.9% for T-tau and -4.9% P-tau;
5 in the 400 mg every fourth week group (n=8) -2.7% for T-tau and -3.3% P-tau; and in the 400
6 mg weekly group (n=5) +2.8% for T-tau and +2.2% P-tau.
7
8
9

10
11 Doody et al presented two large phase 3 studies of solanezumab. EXPEDITION 1 included
12 506 AD patients receiving 400 mg iv solanezumab and 506 AD patients receiving placebo
13 every four weeks for 18 months. EXPEDITION 2 included 521 AD patients receiving
14 solanezumab and 519 AD patients receiving placebo in the same doses and time points as for
15 the first study [54]. The MMSE score of all included patients was between 16-26. CSF levels
16 of A β 40 decreased by 1,902 (95% CI -6660 to +2856) pg/ml in the placebo group and
17 increased by +1,325 (95% CI -3162 to +5813) pg/ml in the solanezumab group in
18 EXPEDITION 1 between baseline and week 80 (P=0.002). In EXPEDITION 2 study A β 40
19 decreased by -876 (95% CI -4342 to +2590) pg/ml in the placebo group and increased by
20 +2157 (95% CI -1212 to +5525) pg/ml in the solanezumab group (P<0.001). For CSF A β 42,
21 in EXPEDITION 1 the placebo group declined by -242 (95% CI -1144 to +660) pg/ml whilst
22 the solanezumab group increased by +471 (95% CI -436 to +1379) pg/ml (P<0.001); whilst in
23 EXPEDITION 2 study the placebo group increased by +324 (95% CI +86 to +561) pg/ml and
24 the solanezumab group by +727 (95% CI +489 to +964) pg/ml (P<0.001). However, there
25 were no significant effects on cognition or CSF levels of T-tau and P-tau between patients
26 treated with solanezumab and placebo.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 In a follow-up trial (EXPEDITION 3), 2100 patients with AD were recruited. As well as
49 narrowing the entry criteria to milder disease (MMSE=20-26) the included patients had to
50 have a positive 18F-florbetapir PET scan i.e. indicating amyloid pathology. This trial failed to
51 reach its primary outcome measure i.e. a significant change in ADAS-Cog14 between the
52 treatment (400 mg solanezumab) and placebo groups after 80 weeks (unpublished data;
53
54
55
56
57
58
59
60

1
2
3 [http://www.alzforum.org/news/conference-coverage/ctad-solanezumab-seen-nudge-ad-ever-](http://www.alzforum.org/news/conference-coverage/ctad-solanezumab-seen-nudge-ad-ever-so-slightly)
4 [so-slightly](http://www.alzforum.org/news/conference-coverage/ctad-solanezumab-seen-nudge-ad-ever-so-slightly)). However, both secondary outcomes (MMSE and Clinical Dementia Rating –
5 Sum of Boxes Score) declined less in the treatment group than in controls. An unexpected
6 finding in this study was a statistically significant increase in P-Tau and borderline significant
7 increase in T-Tau (P=0.06) in the treatment group compared to the placebo group. In all
8 studies, solanezumab induced sharp increases in plasma A β concentrations. Recent data
9 suggest that this may be due to blocking of enzymatic clearance of A β in blood by insulin-
10 degrading enzyme [55].

21 **Ponezumab**

22 Ponezumab is a humanized monoclonal anti-A β antibody that binds to the C-terminal part of
23 A β 40 and only to the soluble form [56]. Ponezumab was tested in a phase 1 study where AD
24 patients (MMSE 16-26), received a single infusion of the drug of either 1 mg/kg, 3 mg/kg, 5
25 mg/kg or 10 mg/kg [57]. There was a dose-dependent increase in plasma A β 40. However,
26 there were no baseline CSF measurements in this study and the only data were from 6 h after
27 the infusion. Since CSF biomarkers only were analyzed in three patients receiving the dose 5
28 mg/kg and three receiving 10 mg/kg, no conclusions can be drawn.

39 **Gantenerumab**

40 Gantenerumab is a fully human IgG1 anti-A β antibody that was derived from a human phage
41 display library and optimized for high-affinity binding with fibrillar A β [58]. In a phase 3
42 study of gantenerumab, 770 patients with prodromal AD with a MMSE score \geq 24 received
43 injections of 105 mg, 225 mg gantenerumab or placebo every fourth week until week 104.
44 The CSF data from this trial was presented at the 2016 Springfield meeting
45 (http://www.siumed.edu/cpd/alzheimer/pdf/abstractbook_2016.pdf). There was no effect on
46 CSF A β 42 levels. However a significant reduction in T-tau level was observed after 2 years in
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the 225 mg group compared with placebo, accompanied by a dose-dependent decrease in P-
4 tau and neurogranin.
5
6

8 **Intravenous immunoglobulins**

9
10 An alternative to using antibodies directed specifically against A β is to trial more generic
11 immunomodulation using intravenous immunoglobulins (IvIg). In a phase 2 multicenter trial
12 of 55 AD patients (MMSE 16-26), patients were randomized to receive a total of three doses;
13 0.1 g/kg every 2 weeks (n=6), 0.25 g/kg every 2 weeks (n=7), 0.4 g/kg every 2 weeks (n=7),
14 0.2 g/kg every 4 weeks (n=7), 0.5 g/kg every 4 weeks (n=8) or 0.8 g/kg IvIg every 4 weeks
15 (n=7) or placebo [59]. There were neither significant effects on memory/cognition nor on CSF
16 levels of T-tau, P-tau, A β 40 or A β 42 between the treatment groups and placebo at week 24.
17 Plasma levels of A β 42 were significantly decreased in individuals receiving 0.25 g/kg dosed
18 every 2 weeks compared with placebo; this was not paralleled in plasma A β 40 levels.
19
20
21
22
23
24
25
26
27
28
29
30

31 **Semagacestat**

32
33 Semagacestat is a γ -secretase inhibitor. It is not selective for APP but also targets Notch
34 among other substrates [60]. In a clinical trial of 52 AD patients who received 100 mg, 140
35 mg semagacestat or placebo daily for 14 weeks, no difference in CSF T-tau and P-tau were
36 found between baseline and at 14 weeks for any of the groups. The change in the placebo
37 group (n=11) was +1.5% for T-tau and -0.8% for P-tau; for the 100 mg group (n=17), +4.7%
38 for T-tau and +3.5% for P-tau; and for the 140 mg group (n=12) +7.7% for T-tau and +2.8%
39 for P-tau [53]. In a large multicenter clinical trial, AD patients with MMSE between 16-26
40 were randomized to either 100 (n=482) or 140 mg (n=495) semagacestat daily or placebo
41 (n=485) for 76 weeks [61]. There were no significant effects on cognition between the
42 treatment groups and placebo groups. CSF data which were available on a very small sample
43 were presented as annualized change: A β 42 increased in the placebo group (n=10) by 11 \pm 88
44 pg/ml and decreased in both the 100 mg (n=19, -40 \pm 110 pg/ml) and also in and 140 mg
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(n=18, -36 ± 183 pg/ml) semagacestat groups. The same trend was observed for the annualized change in A β 1-40: in the placebo group (n=10) there was an increase of 88 ± 847 pg/ml, with decreases on -11 ± 1151 pg/ml and -599 ± 1786 pg/ml in the 100 (n=19) and 140 mg (n=18) semagacestat groups respectively. For T-tau there was an annualized increase of $+95\pm 117$ pg/ml in the placebo group (n=10), a decrease of -44 ± 219 pg/ml in the 100 mg semagacestat group (n=17) but an increase of $+40\pm 128$ pg/ml in the 140 mg (n=18) semagacestat groups. The annualized change of P-tau in the placebo group (n=10) was $+11\pm 7$ pg/ml, with decreases of -7 ± 15 and -4 ± 11 pg/ml, respectively, in the 100 (n=19) and 140 mg (n=18) semagacestat groups. Treatment with semagacestat has also been shown to result in a dose-dependent increase in the A β isoforms A β 1-14, A β 1-15 and A β 1-16 [62].

Tramiprosate

Tramiprosate (3-amino-1-propanesulfonic acid, 3APS) is an amyloid-binding agent that in transgenic animal studies has been shown to reduce oligomeric and fibrillar (plaque) A β [63]. In a phase 2 study, 58 AD patients with an MMSE score of 13-25 were randomized to either 50, 100, 150 mg tramiprosate or placebo twice daily. Tramiprosate had no effect on memory or cognition or CSF levels of T-tau and A β 40. However, there was a dose-dependent decrease in CSF A β 42 levels [64].

Tideglusib

Tideglusib is a thiadiazolidinone which irreversibly inhibits GSK-3. GSK-3 has in preclinical studies been shown to phosphorylate tau [65] and regulate the production of A β [66]. In this study, AD patients with an MMSE score of 14-26 were randomized to 500 mg (n=50) or 1000 mg tideglusib once daily (n=81), 1000 mg tideglusib every other day (n=90) or placebo (n=85) for 26 weeks [67]. There was no clinical benefit of the treatment in this study. Only a few patients were sampled for CSF; 15 treated with tideglusib and six with placebo. There was no change in A β 42 (tideglusib -7.1 ± 132.2 vs. placebo $+7.9\pm 106.3$ pg/ml, $P=0.81$), T-tau (-

1
2
3 2.5±129.2 vs. -45.8±135.8 pg/ml, P=0.50), P-tau181 (+1.9±22.7 vs. +25.2±37.3 pg/ml,
4
5 P=0.09) or P-tau396 (-0.18±0.64 vs. +0.18±0.49 pg/ml, P=0.23).
6
7

8 **Resveratrol**

9
10 Resveratrol is an activator of sirtuin 1 (SIRT1), a histone deacetylase involved in aging and
11 longevity [68]. This multicenter phase 2 study included 119 AD patients with MMSE scores
12 of 14-26. The patients were randomized to either resveratrol in 500 mg increments every 13
14 weeks i.e. 500 mg every morning, 500 mg twice daily, 1000 mg every morning and 500 every
15 afternoon and finally 1000 mg twice daily (n=64) or placebo (n=55) [69]. There was no
16 clinical benefit of the treatment in this study and no significant effects on either CSF levels of
17 Aβ42, T-tau or P-tau between the groups (data not presented in the paper).
18
19
20
21
22
23
24
25
26

27 **Avagacestat**

28 Avagacestat is a γ-secretase inhibitor evaluated in a multicenter phase 2 study. 209 AD
29 patients (MMSE 16-26), were randomized to receive either 25, 50, 100 or 125 mg avagacestat
30 or placebo once daily for 24 weeks [70]. There was no effect on cognition in the 25 and 50
31 mg groups compared with placebo but a trend for worsening in the 100 and 125 mg groups.
32 No significant changes of CSF T-tau or P-tau were observed between the treatment groups
33 and placebo. For Aβ40 and Aβ42 a significant decrease was observed in the 125 mg group
34 only compared to placebo.
35
36
37
38
39
40
41
42
43
44

45 **Antioxidants**

46 In a three arm study of AD (MMSE 16-30), 26 patients received 800 IU vitamin E, 500 mg
47 vitamin C and 900 mg α-lipoic acid daily, 26 patients received 400 mg coenzyme Q three
48 times a day, and 26 patients received placebo [71]. No significant effects on memory and
49 cognition or levels of Aβ42, T-tau or P-tau were observed between the groups.
50
51
52
53
54
55
56
57
58
59
60

Expert commentary

None of the clinical trials for AD described above achieved any significant effect on memory or cognition. There are several likely reasons for this. First of all, many of the studies included patients with low MMSE scores, and in some cases down to 14, indicating already advanced cognitive and memory decline. At this stage of disease, it is likely to be too late to halt the spread of pathology and influence the already advanced neurodegeneration that is present in AD at this stage. Furthermore, the diagnosis of AD has often been based on the clinical McKhann criteria from 1984 [72] which did not require biomarker evidence of AD pathology. Data from some studies have indicated that around 15-20% of the included patients did not have Alzheimer pathology [73,74]. Having a significant proportion of patients with other diagnoses in an AD trial not only exposes patients who are very unlikely to benefit to potential side-effects, but also considerably reduces the power to identify a positive effect of a drug if one is present. New criteria for AD take biomarkers – both PET and CSF based – into account [22] but very few clinical trials have finished since these criteria were launched. If the correct individuals were targeted, it is of course possible that the drugs tested in these trials were not targeting the correct pathology. For example, of the two major immunotherapy drugs that failed at phase 3 – solanezumab only binds soluble monomeric A β whereas bapineuzumab binds both soluble and fibrillar A β . By contrast, the drug that has shown hints of efficacy in terms of an effect on cognition – albeit only in a phase 1b trial – is aducanumab which is an antibody that only binds aggregated A β , and especially so in the parenchyma [75]. Therefore, it might be important which A β form that is targeted, and CSF studies with the potential to delineate different A β moieties may become very important as entry inclusion or for stratification. In terms of outcome measures, whilst alteration in A β load may be an indicator of target engagement, and potentially a correlate of efficacy in primary or secondary prevention studies, demonstration of an effect on neurodegeneration is likely to require

1
2
3 evidence of a change in other markers – perhaps particularly T-tau, P-tau, or NFL; or perhaps
4 synaptic function, as might be indicated by Ng. With the exception of an effect with
5 bapineuzumab, such changes have not been demonstrated in trials to date. Whilst this is likely
6 to simply reflect a lack of effect on downstream neurodegeneration which may in turn reflect
7 one or more of the wrong drug being given at the wrong dose at the wrong time, it is notable
8 that in most cases only subsets of patients had serial CSF examination, limiting power to
9 detect change.
10
11
12
13
14
15
16
17
18
19

20 **So what can CSF biomarkers aid with in clinical trials for AD?**

21 (1) Inclusion criteria. For an AD trial, is it vital to demonstrate that the individual in question
22 has AD pathology. A biomarker of amyloid deposition is of utmost importance, and currently,
23 amyloid PET or analysis of CSF levels of A β 42 can be used for this purpose. (2) Going
24 earlier. It is increasingly evident that it will be necessary to start treatment as early as
25 possible, before neuronal damage becomes irreversible – it becomes ever more important to
26 use biomarkers to demonstrate the underlying pathology the earlier in the disease process the
27 trial is targeting. There are a number of reasons why CSF may be preferred to PET for the
28 demonstration of A β pathology. Several studies have shown that CSF levels of A β 42 drop
29 before amyloid PET becomes positive; CSF allows for various forms of A β pathology – not
30 just fibrillary forms – to be demonstrated. Measurement of CSF A β 42 is also considerably
31 cheaper than amyloid PET – and may be easier to roll out to the general population as/when
32 such drugs enter the market. (3) A robust measure of neurodegeneration is required to
33 demonstrate an effect on neurodegeneration. Whilst MR measures of atrophy or change in tau
34 PET may provide an alternative, the multiplicity of CSF measures of different aspects of
35 neurodegeneration potentially provides invaluable insights into the disease process. (4)
36 Proximity markers. To improve the turnaround for AD clinical trials a proximity marker of
37 upcoming memory problems and cognition would be desirable. Since memory and cognition
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 problems in AD are linked to neuronal cell death it is likely that biomarkers of neuronal cell
4
5 death may provide the link between amyloid deposition and the onset of neurodegeneration.
6
7 Tau PET is unlikely to be widely available or cost effective enough to be used in this context,
8
9 whilst measures of T-tau, P-Tau, NFL and measures of synaptic density (Ng) can be measured
10
11 in parallel from the same sample. Whilst no disease-modifying trial has so far shown any
12
13 clinical effect, and so it is not surprising that no clear effects on T-tau have been found,
14
15 neurogranin data from the gantenerumab trial has not yet been published and NFL and has not
16
17 been evaluated in any trials at all. A detailed understanding of the longitudinal stability of
18
19 these biomarkers and changes in both health and disease will be vital for these purposes; as
20
21 will a much larger update of CSF sampling in clinical trials rather than the typically ad hoc
22
23 subgroup sampling that currently often occurs.
24
25
26
27
28
29
30

31 **Five year view**

32
33 It will be increasingly important to use biomarkers to enrich the study populations for subjects
34
35 with the pathologies against which the drug candidate is directed, and to stratify in terms of
36
37 rate of neurodegeneration and timing in relation to symptom onset. This will determine that
38
39 the drug is given only to individuals who may benefit from treatment, and allow for
40
41 recruitment of individuals with presymptomatic disease, and for rationale trial design to
42
43 demonstrate disease modification. Therefore, our prediction is that demonstration of amyloid
44
45 pathology using either measures of CSF A β 42 or amyloid PET will become a mandatory trial
46
47 inclusion. Serial analysis of amyloid pathology is also likely to be used more in order to
48
49 follow drug effect on amyloid pathology in the trials where that mechanism is targeted. We
50
51 also foresee a more general shift from PET to CSF analyses given that several biomarkers can
52
53 be analyzed on the CSF from a single lumbar puncture and samples stored for future analysis
54
55 (future proofing) in contrast to PET which can only measure certain aspects of pathology and
56
57
58
59
60

1
2
3 requires several different scans. We predict the increasing use of CSF studies in very early
4 (dose finding/phase 1 studies) to provide proof of concept that the drug in question reaches
5 the brain at sufficient concentration. Newer methodologies that can measure the dynamics and
6 turnover of proteins in the CSF will also increasingly be used to demonstrate in vivo effects of
7 putative therapies in very small patient numbers [76]. When it comes to evaluation of the
8 treatment effect on neuronal degeneration serial CSF measures of NFL and T-tau will be used
9 more extensively. In addition to NFL, T-tau and A β 42, it is likely that there will be an
10 increasing availability of newer biomarkers that can probe other aspects of disease activity.
11 Biomarkers already available or emerging include not only P-tau as a marker of tau
12 phosphorylation and neurogranin as a marker of synapse and dendrite dysfunction but also
13 YKL-40 and sTREM2, markers of astroglial activity (Figure 1). New multiplex CSF assays
14 which allow for very large numbers of proteins to be measures simultaneously and at
15 femtomolar concentrations, will allow for numerous aspects of pathology to be measured
16 concurrently – and consequently for the effects of putative treatments to be evaluated with
17 unprecedented detail. Inevitably therefore, CSF studies will enter the mainstream becoming a
18 vital part of the early evaluation of putative drugs, as well as inclusion, safety and outcome
19 measures for clinical trials.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Figure legends**

44 **Figure 1.** CSF biomarkers and their use in clinical trials.
45
46
47

48 **References**

- 49
50
51
52 1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet*
53 2006;368:387-403.
54 2. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts,
55 and estimates from the Framingham Study. *Lancet Neurol* 2007;6:1106-14.
56 3. Hebert LE, Weuve J, Scherr PA et al. Alzheimer disease in the United States
57 (2010-2050) estimated using the 2010 census. *Neurology* 2013;80:1778-83.
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
4. Olsson B, Zetterberg H, Hampel H et al. Biomarker-based dissection of neurodegenerative diseases. *Prog Neurobiol* 2011;95:520-34.
5. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. *Allg Z Psychiat* 1907;64:146-8.
6. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science* 1992;256:184-5.
7. Olsson B, Lautner R, Andreasson U et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol* 2016;15:673-84.
8. Wallin AK, Blennow K, Zetterberg H et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. *Neurology* 2010;74:1531-7.
9. Riemenschneider M, Wagenpfeil S, Vanderstichele H et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. *Mol Psychiatry* 2003;8:343-7.
10. Hesse C, Rosengren L, Andreasen N et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. *Neurosci Lett* 2001;297:187-90.
11. Grundke-Iqbal I, Iqbal K, Tung YC et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc Natl Acad Sci U S A* 1986;83:4913-7.
12. Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. *Brain* 2006;129:3035-41.
13. Blom ES, Giedraitis V, Zetterberg H et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. *Dement Geriatr Cogn Disord* 2009;27:458-64.
14. Samgard K, Zetterberg H, Blennow K et al. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. *Int J Geriatr Psychiatry* 2010;25:403-10.
15. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun* 1984;120:885-90.
16. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 1987;325:733-6.
17. Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 1991;349:704-6.
18. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. *Nat Genet* 1995;11:219-22.
19. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 1995;269:973-7.
20. Jervis GA. Early senile dementia in mongoloid idiocy. *Am J Psychiatry* 1948;105:102-6.
21. Blennow K, Mattsson N, Scholl M et al. Amyloid biomarkers in Alzheimer's disease. *Trends Pharmacol Sci* 2015;36:297-309.
22. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263-9.
23. Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurol* 2006;5:228-34.

- 1
- 2
- 3 24. Wiltfang J, Esselmann H, Bibl M et al. Amyloid beta peptide ratio 42/40 but not
- 4 A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. *J*
- 5 *Neurochem* 2007;101:1053-9.
- 6 25. Zetterberg H. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker
- 7 for Neurodegeneration. *Neuron* 2016;91:1-3.
- 8 26. Zetterberg H, Skillback T, Mattsson N et al. Association of Cerebrospinal Fluid
- 9 Neurofilament Light Concentration With Alzheimer Disease Progression. *JAMA Neurol*
- 10 2016;73:60-7.
- 11 27. de Jong D, Jansen RW, Pijnenburg YA et al. CSF neurofilament proteins in the
- 12 differential diagnosis of dementia. *J Neurol Neurosurg Psychiatry* 2007;78:936-8.
- 13 28. Landqvist Waldo M, Frizell Santillo A, Passant U et al. Cerebrospinal fluid
- 14 neurofilament light chain protein levels in subtypes of frontotemporal dementia. *BMC Neurol*
- 15 2013;13:54.
- 16 29. Sjogren M, Rosengren L, Minthon L et al. Cytoskeleton proteins in CSF
- 17 distinguish frontotemporal dementia from AD. *Neurology* 2000;54:1960-4.
- 18 30. Skillback T, Farahmand B, Bartlett JW et al. CSF neurofilament light differs in
- 19 neurodegenerative diseases and predicts severity and survival. *Neurology* 2014;83:1945-53.
- 20 31. Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal
- 21 fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian
- 22 disorders. *Arch Neurol* 2012;69:1445-52.
- 23 32. Magdalino NK, Paterson RW, Schott JM et al. A panel of nine cerebrospinal
- 24 fluid biomarkers may identify patients with atypical parkinsonian syndromes. *J Neurol*
- 25 *Neurosurg Psychiatry* 2015;86:1240-7.
- 26 33. Weydt P, Oeckl P, Huss A et al. Neurofilament levels as biomarkers in
- 27 asymptomatic and symptomatic familial amyotrophic lateral sclerosis. *Ann Neurol*
- 28 2016;79:152-8.
- 29 34. van Eijk JJ, van Everbroeck B, Abdo WF et al. CSF neurofilament proteins
- 30 levels are elevated in sporadic Creutzfeldt-Jakob disease. *J Alzheimers Dis* 2010;21:569-76.
- 31 35. Steinacker P, Blennow K, Halbgebauer S et al. Neurofilaments in blood and
- 32 CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. *Sci Rep*
- 33 2016;6:38737.
- 34 36. Thorsell A, Bjerke M, Gobom J et al. Neurogranin in cerebrospinal fluid as a
- 35 marker of synaptic degeneration in Alzheimer's disease. *Brain Res* 2010;1362:13-22.
- 36 37. Kvartsberg H, Duits FH, Ingelsson M et al. Cerebrospinal fluid levels of the
- 37 synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's
- 38 disease. *Alzheimers Dement* 2015;11:1180-90.
- 39 38. Kvartsberg H, Portelius E, Andreasson U et al. Characterization of the
- 40 postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from
- 41 Alzheimer's disease patients and healthy controls. *Alzheimers Res Ther* 2015;7:40.
- 42 39. Hellwig K, Kvartsberg H, Portelius E et al. Neurogranin and YKL-40:
- 43 independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
- 44 *Alzheimers Res Ther* 2015;7:74.
- 45 40. Kester MI, Teunissen CE, Crimmins DL et al. Neurogranin as a Cerebrospinal
- 46 Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. *JAMA Neurol*
- 47 2015;72:1275-80.
- 48 41. Wellington H, Paterson RW, Portelius E et al. Increased CSF neurogranin
- 49 concentration is specific to Alzheimer disease. *Neurology* 2016;86:829-35.
- 50 42. Portelius E, Zetterberg H, Skillback T et al. Cerebrospinal fluid neurogranin:
- 51 relation to cognition and neurodegeneration in Alzheimer's disease. *Brain* 2015;138:3373-85.
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3 43. Tarawneh R, D'Angelo G, Crimmins D et al. Diagnostic and Prognostic Utility
- 4 of the Synaptic Marker Neurogranin in Alzheimer Disease. *JAMA Neurol* 2016.
- 5 44. Brinkmalm A, Brinkmalm G, Honer WG et al. SNAP-25 is a promising novel
- 6 cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. *Mol*
- 7 *Neurodegener* 2014;9:53.
- 8 45. Bereczki E, Francis PT, Howlett D et al. Synaptic proteins predict cognitive
- 9 decline in Alzheimer's disease and Lewy body dementia. *Alzheimers Dement* 2016;12:1149-
- 10 58.
- 11 46. Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization
- 12 (AN1792) in patients with AD in an interrupted trial. *Neurology* 2005;64:1553-62.
- 13 47. Johnson-Wood K, Lee M, Motter R et al. Amyloid precursor protein processing
- 14 and A beta42 deposition in a transgenic mouse model of Alzheimer disease. *Proc Natl Acad*
- 15 *Sci U S A* 1997;94:1550-5.
- 16 48. Salloway S, Sperling R, Gilman S et al. A phase 2 multiple ascending dose trial
- 17 of bapineuzumab in mild to moderate Alzheimer disease. *Neurology* 2009;73:2061-70.
- 18 49. Rinne JO, Brooks DJ, Rossor MN et al. 11C-PiB PET assessment of change in
- 19 fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a
- 20 phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurol* 2010;9:363-
- 21 72.
- 22 50. Blennow K, Zetterberg H, Rinne JO et al. Effect of immunotherapy with
- 23 bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate
- 24 Alzheimer disease. *Arch Neurol* 2012;69:1002-10.
- 25 51. Salloway S, Sperling R, Fox NC et al. Two phase 3 trials of bapineuzumab in
- 26 mild-to-moderate Alzheimer's disease. *N Engl J Med* 2014;370:322-33.
- 27 52. DeMattos RB, Bales KR, Cummins DJ et al. Peripheral anti-A beta antibody
- 28 alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model
- 29 of Alzheimer's disease. *Proc Natl Acad Sci U S A* 2001;98:8850-5.
- 30 53. Lachno DR, Romeo MJ, Siemers ER et al. Validation of ELISA methods for
- 31 quantification of total tau and phosphorylated-tau181 in human cerebrospinal fluid with
- 32 measurement in specimens from two Alzheimer's disease studies. *J Alzheimers Dis*
- 33 2011;26:531-41.
- 34 54. Doody RS, Thomas RG, Farlow M et al. Phase 3 trials of solanezumab for mild-
- 35 to-moderate Alzheimer's disease. *N Engl J Med* 2014;370:311-21.
- 36 55. Portelius E, Mattsson N, Pannee J et al. Ex vivo 18O-labeling mass
- 37 spectrometry identifies a peripheral amyloid beta clearance pathway. *Mol Neurodegener*
- 38 2017;12:18.
- 39 56. La Porte SL, Bollini SS, Lanz TA et al. Structural basis of C-terminal beta-
- 40 amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease.
- 41 *J Mol Biol* 2012;421:525-36.
- 42 57. Burstein AH, Zhao Q, Ross J et al. Safety and pharmacology of ponezumab (PF-
- 43 04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate
- 44 Alzheimer disease. *Clin Neuropharmacol* 2013;36:8-13.
- 45 58. Ostrowitzki S, Deptula D, Thurfjell L et al. Mechanism of amyloid removal in
- 46 patients with Alzheimer disease treated with gantenerumab. *Arch Neurol* 2012;69:198-207.
- 47 59. Dodel R, Rominger A, Bartenstein P et al. Intravenous immunoglobulin for
- 48 treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind,
- 49 placebo-controlled, dose-finding trial. *Lancet Neurol* 2013;12:233-43.
- 50 60. Henley DB, May PC, Dean RA et al. Development of semagacestat
- 51 (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
- 52 *Expert Opin Pharmacother* 2009;10:1657-64.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3 61. Doody RS, Raman R, Sperling RA et al. Peripheral and central effects of
- 4 gamma-secretase inhibition by semagacestat in Alzheimer's disease. *Alzheimers Res Ther*
- 5 2015;7:36.
- 6 62. Portelius E, Dean RA, Gustavsson MK et al. A novel Aβ isoform pattern in
- 7 CSF reflects gamma-secretase inhibition in Alzheimer disease. *Alzheimers Res Ther*
- 8 2010;2:7.
- 9 63. Caltagirone C, Ferrannini L, Marchionni N et al. The potential protective effect
- 10 of tramiprosate (homotaurine) against Alzheimer's disease: a review. *Aging Clin Exp Res*
- 11 2012;24:580-7.
- 12 64. Aisen PS, Saumier D, Briand R et al. A Phase II study targeting amyloid-beta
- 13 with 3APS in mild-to-moderate Alzheimer disease. *Neurology* 2006;67:1757-63.
- 14 65. Hanger DP, Hughes K, Woodgett JR et al. Glycogen synthase kinase-3 induces
- 15 Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes
- 16 and neuronal localisation of the kinase. *Neurosci Lett* 1992;147:58-62.
- 17 66. Phiel CJ, Wilson CA, Lee VM et al. GSK-3α regulates production of
- 18 Alzheimer's disease amyloid-beta peptides. *Nature* 2003;423:435-9.
- 19 67. Lovestone S, Boada M, Dubois B et al. A phase II trial of tideglusib in
- 20 Alzheimer's disease. *J Alzheimers Dis* 2015;45:75-88.
- 21 68. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins
- 22 extend *Saccharomyces cerevisiae* lifespan. *Nature* 2003;425:191-6.
- 23 69. Turner RS, Thomas RG, Craft S et al. A randomized, double-blind, placebo-
- 24 controlled trial of resveratrol for Alzheimer disease. *Neurology* 2015;85:1383-91.
- 25 70. Coric V, van Dyck CH, Salloway S et al. Safety and tolerability of the gamma-
- 26 secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
- 27 *Arch Neurol* 2012;69:1430-40.
- 28 71. Galasko DR, Peskind E, Clark CM et al. Antioxidants for Alzheimer disease: a
- 29 randomized clinical trial with cerebrospinal fluid biomarker measures. *Arch Neurol*
- 30 2012;69:836-41.
- 31 72. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's
- 32 disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of
- 33 Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939-44.
- 34 73. Landau SM, Horng A, Fero A et al. Amyloid negativity in patients with
- 35 clinically diagnosed Alzheimer disease and MCI. *Neurology* 2016;86:1377-85.
- 36 74. Beach TG, Monsell SE, Phillips LE et al. Accuracy of the clinical diagnosis of
- 37 Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. *J*
- 38 *Neuropathol Exp Neurol* 2012;71:266-73.
- 39 75. Sevigny J, Chiao P, Bussiere T et al. The antibody aducanumab reduces Aβ
- 40 plaques in Alzheimer's disease. *Nature* 2016;537:50-6.
- 41 76. Bateman RJ, Siemers ER, Mawuenyega KG et al. A gamma-secretase inhibitor
- 42 decreases amyloid-beta production in the central nervous system. *Ann Neurol* 2009;66:48-54.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60




Figure 1. CSF biomarkers and their use in clinical trials.

185x172mm (300 x 300 DPI)

Only